Accolade, Inc.

Equities

ACCD

US00437E1029

Healthcare Facilities & Services

Market Closed - Nasdaq 01:30:00 29/06/2024 am IST 5-day change 1st Jan Change
3.58 USD -43.97% Intraday chart for Accolade, Inc. -41.69% -70.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Decline in Late Afternoon Trading MT
Sector Update: Health Care MT
Top Midday Decliners MT
Barclays Lowers Price Target on Accolade to $5.50 From $11, Maintains Equalweight Rating MT
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation MT
Canaccord Genuity Adjusts Price Target on Accolade to $13 From $16, Maintains Buy Rating MT
Needham Cuts Accolade's Price Target to $8 From $13, Keeps Buy Rating MT
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell MT
Top Premarket Decliners MT
Morgan Stanley Halves Price Target on Accolade to $6 From $12, Keeps Equalweight Rating MT
Truist Adjusts Price Target on Accolade to $9 From $14, Maintains Buy Rating MT
Accolade, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2024 CI
Accolade Fiscal Q1 Net Loss Narrows, Revenue Rises; Fiscal Q2 Revenue Outlook Set -- Shares Fall After Hours MT
Transcript : Accolade, Inc., Q1 2025 Earnings Call, Jun 27, 2024
Accolade Guides For Q2 Revenue of $104-$106 Million, vs CIQ Analyst Consensus of $113 Million; FY Revenue Seen at $460-$475 Million, vs Consensus of $460 Million MT
Earnings Flash (ACCD) ACCOLADE Posts Q1 Revenue $110.5M, vs. Street Est of $105.2M MT
Accolade, Inc. Welcomes Noom to Trusted Partner Ecosystem CI
Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating MT
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating MT
Transcript : Accolade, Inc., Q4 2024 Earnings Call, Apr 25, 2024
Accolade, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended February 29, 2024 CI
Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating MT
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President CI
Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Leerink Partners Initiates Accolade at Outperform Rating With $16 Price Target MT
Chart Accolade, Inc.
More charts
Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.58 USD
Average target price
8.467 USD
Spread / Average Target
+136.50%
Consensus
  1. Stock Market
  2. Equities
  3. ACCD Stock
  4. News Accolade, Inc.
  5. Stephens Initiates Accolade at Overweight With $18 Price Target